Anthim obiltoxaximab regulatory update

FDA accepted a BLA for Anthim obiltoxaximab from Elusys to treat and prevent inhalational anthrax. The PDUFA date is March 18, 2016. The high-affinity humanized mAb against the Bacillus anthracis pro...